E-cadherin and Large Bowel Cancer
Author Information
Author(s): A.R. Kinsella, B. Green, G.C. Lepts, C.L. Hill, G. Bowie, B.A. Taylor
Primary Institution: Royal Liverpool University Hospital
Hypothesis
Can reduced E-cadherin expression be correlated with the progression of tumours to the metastatic state?
Conclusion
Reduced E-cadherin expression is observed more frequently with tumour spread, but it is probably not a predictor of metastatic potential in large bowel tumours.
Supporting Evidence
- 12 of the 40 patients with carcinoma had lymph node involvement at the time of surgery.
- Only 9 of the 12 patients with lymph node involvement showed reduced E-cadherin expression.
- Overall, only 11 of the 17 patients with tumor spread at the time of surgery exhibited reduced E-cadherin expression.
Takeaway
This study looked at a protein called E-cadherin in cancer samples to see if it could help predict if the cancer would spread. They found that while some cancers with less E-cadherin did spread, many did not, so it's not a reliable sign.
Methodology
Frozen sections of samples from 44 patients were examined for E-cadherin expression using immunofluorescent staining techniques.
Limitations
The study may not have captured all negative staining cells due to tumor heterogeneity, and the assay might not be sensitive enough to detect functional E-cadherin.
Participant Demographics
Patients undergoing surgery for suspected adenocarcinoma, including 43 with large bowel cancer and one with liver recurrence.
Statistical Information
P-Value
0.001
Confidence Interval
95% CI: 13 to 72%
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website